Addressing unmet clinical needs and evolving patient outcomes require more than conventional approaches; they call for ingenuity, creative solutions, and the ability to see the unseen. Among these innovations, the development of value-added medicines stands out as a unique and transformative approach. Unlike traditional generics, these medicines leverage the potential of known molecules to deliver enhanced solutions to patients whose requirements aren’t met by current treatment options.

At Colonis, with over 15 years of experience in developing and commercialising value-added medicines, we have a deep understanding of the significant improvements they can bring to clinical outcomes and the enhanced quality of life for patients. Read on to discover more about how these important advancements hold the power to reshape the landscape of healthcare and ultimately improve patient outcomes.

What are value-added medicines?

Value-added medicines are products where known molecules are reimagined beyond their existing applications to offer alternative treatment options in patient care. The approach to crafting these products can be found in a number of strategic avenues:

• Drug reformulation or repurposing: Repurposing medicines is the process of developing distinct formulations or presentations of existing molecules. This practice can enhance the accuracy of dosing, as well as the practicality and ease of administration of products, ensuring that patients receive medicines tailored to their unique needs.

• Drug repositioning: Drug repositioning explores new therapeutic possibilities for existing products. By finding alternative applications, this approach unlocks the untapped potential of medications, expanding treatment options and addressing previously unmet clinical needs.

• Drug combination: This refers to the integration of two or more drugs into a single dosage, or the fusion of drugs with devices or other services, to streamline treatment regimens and amplify the effectiveness of medications.

In the right hands, value-added medicines provide a host of benefits to patients and healthcare providers, such as:

• Ease of administration: Repurposing medicines is a powerful way to ensure that patients can receive an accurate dose of their medication in a way that aids administration. For example, prescribing oral solutions over tablet formulations when treating very young or elderly patient populations.

• Improved patient adherence and efficacy of medication: Treatments that provide the same medicine in a convenient formulation to suit patient needs can lessen the stress around taking medication and, in turn, improve the adherence to taking the medicine itself.

• Increased treatment options: Value-added medicines provide broader treatment options to patients and greater flexibility to the caregivers serving them. This allows for a more tailored approach and can improve patient outcomes.

Our commitment to rethinking conventions actively contributes to this transformative landscape, where patient-centricity meets innovation. With Colonis, these important medicines become more than just treatments; they emerge as catalysts for tailored healthcare experiences.

Discover our success story to learn more about our achievements in repurposing medicines.

Precision development: Colonis’ approach to value-added medicines

Our research and development strategy for every product is unique, but each starts with thorough market analysis and evaluation to ascertain the medical and commercial viability of reformulating or repurposing the product. Upon identifying an opportunity to add value, we draft a well-structured reformulation proposal that provides a clear and compelling rationale for the project’s progression. Our team of scientists and reformulation experts then spearhead the design and development of our medicines, leveraging our deep understanding of regulatory requirements to bring the product to market.

Investing in the future: Colonis’ expertise in value-added medicines

Our success stems from our commitment to creating value, a core element of our identity. With an extensive background in repurposing medicines, we’ve obtained marketing authorisations and commercialised 12 molecules across 24 different dosage formulations since we first achieved marketing authorisation for a repurposed medicine in 2015.

This wealth of experience forms our unique value proposition. We see the bigger picture for our value-added medicines and during post-development, we continue to add value by making significant reinvestments in ongoing research and development. Our focus on the future extends the life cycles of these medicines, as we continually adapt them to meet evolving patient needs, effectively addressing gaps in the market. We then share our expertise with our value-aligned partners, allowing for further expansion into new markets.

Contact us today to explore partnership opportunities and be a part of redefining the landscape of patient-focused, value-added solutions.

GB-CPL-0-047
January 2024